var data={"title":"Bleomycin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bleomycin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5749?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bleomycin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bleomycin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=bleomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bleomycin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708640\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">It is recommended that bleomycin be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents. Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pulmonary toxicity: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Pulmonary fibrosis is the most severe toxicity associated with bleomycin. The most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis. Its occurrence is higher in elderly patients and in those receiving more than 400 units total dose, but pulmonary toxicity has been observed in young patients and those treated with low doses.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Idiosyncratic reaction: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in approximately 1% of lymphoma patients treated with bleomycin.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141845\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Blenoxane;</li>\n      <li>Bleomycin Injection, USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141887\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Antibiotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141849\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The risk for pulmonary toxicity increases with age &gt;70 years and cumulative lifetime dose of &gt;400 units. <b>International considerations:</b> Dosages below expressed as USP units; 1 USP unit = 1 mg (by potency) = 1,000 international units (Stefanou 2001). During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Hodgkin lymphoma (off-label dosing):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>ABVD regimen:</i> 10 units/m<sup>2</sup> days 1 and 15 of a 28-day treatment cycle (in combination with doxorubicin, vinblastine, and dacarbazine) (Straus 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>BEACOPP regimen:</i> 10 units/m<sup>2</sup> day 8 of a 21-day treatment cycle (in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) (Dann 2007, Diehl 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Stanford V regimen:</i> 5 units/m<sup>2</sup>/dose in weeks 2, 4, 6, 8, 10 and 12 (in combination with mechlorethamine, vinblastine, vincristine, doxorubicin, etoposide, and prednisone) (Horning 2002; Horning 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Test dose for lymphoma patients:</b> IM, IV, SubQ: Due to the possibility of an anaphylactoid reaction, the manufacturer recommends administering bleomycin 2 units or less before the first 2 doses; if no acute reaction occurs, then the regular dosage schedule may be followed. Monitor carefully, particularly following the first 2 doses. <b>Note:</b> Test doses may not be predictive of a reaction (Lam 2005) and/or may produce false-negative results.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Testicular cancer (off-label dosing):</b> IV: BEP regimen: 30 units/dose days 1, 8, and 15 of a 21-day treatment cycle for 4 cycles (in combination with etoposide and cisplatin) (Culine 2008; Nichols 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Malignant pleural effusion:</b> Intrapleural: 60 units as a single instillation; mix in 50 to 100 mL of NS</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Ovarian germ cell cancer (off-label use):</b> BEP regimen: IV: 30 units/dose days 1, 8, and 15 of a 21-day treatment cycle for 3 cycles (in combination with etoposide and cisplatin) (Williams 1994) <b>or</b> 15 units/m<sup>2</sup> day 1 of a 21-day treatment cycle for 4 cycles (in combination with etoposide and cisplatin) (Cushing 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141871\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=bleomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Bleomycin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> The risk for pulmonary toxicity increases with cumulative lifetime dose of &gt;400 units. <b>International considerations:</b> Dosages below expressed as USP units; 1 USP unit = 1 mg (by potency) = 1,000 international units (Stefanou 2001). During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ABVD regimen (high-risk disease): Children and Adolescents: IV: 10 units/m<sup>2</sup> days 1 and 15 of a 28-day treatment cycle (in combination with doxorubicin, vinblastine, and dacarbazine) for up to 6 cycles (Hutchinson 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ABVE-PC (intermediate-risk or high-risk disease): Children and Adolescents: IV or SubQ: 5 units/m<sup>2</sup> on day 1 and 10 units/m<sup>2</sup> on day 8 of a 21-day cycle (in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide) for 2 to 4 cycles, (Dharmarajan 2015; Friedman 2014; Schwartz 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BEACOPP (high-risk disease): Children and Adolescents: IV: 10 units/m<sup>2</sup> on day 7 of a 21-day treatment cycle (in combination with etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) for 4 cycles (Kelly 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stanford V (high-risk disease): Adolescent &ge;16 years: IV: 5 units/m<sup>2</sup> in weeks 2, 4, 6, 8, 10, and 12 of a single 12-week treatment cycle (in combination with mechlorethamine, vinblastine, vincristine, doxorubicin, etoposide, and prednisone) (Gordon 2013; Horning 2000; Horning 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Test dose for lymphoma patients:</b> IM, IV, SubQ: Due to the possibility of an anaphylactoid reaction, the manufacturer recommends administering bleomycin 2 units or less before the first 2 doses; if no acute reaction occurs, then the regular dosage schedule may be followed. Monitor carefully, particularly following the first 2 doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> Test doses may not be predictive of a reaction (Lam 2005) and/or may produce false-negative results.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Germ cell tumors, malignant, high risk (off-label use):</b> BEP regimen (Cushing 2004):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants: IV: 0.5 <b>mg</b>/kg on day 1 of a 21-day treatment cycle (in combination with cisplatin and etoposide) for 4 cycles.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;1 year and Adolescents: IV: 15 units/m<sup>2</sup> on day 1 of a 21-day treatment cycle (in combination with etoposide and cisplatin) for 4 cycles.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14717786\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing. The incidence of pulmonary toxicity is higher in patients &gt;70 years of age.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141851\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer's labeling </i>(creatinine clearance should be estimated using the Cockcroft-Gault formula):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &ge;50 mL/minute: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 40 to 50 mL/minute: Reduce dose to 70% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 30 to 40 mL/minute: Reduce dose to 60% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 20 to 30 mL/minute: Reduce dose to 55% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 20 mL/minute: Reduce dose to 45% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 5 to 10 mL/minute: Reduce dose to 40% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The following adjustments have also been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aronoff 2007: Adults: Continuous renal replacement therapy (CRRT): Reduce dose to 75% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Kintzel 1995: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 46 to 60 mL/minute: Reduce dose to 70% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 31 to 45 mL/minute: Reduce dose to 60% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute: Consider use of alternative drug</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5526919\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); however, adjustment for hepatic impairment is not necessary (King 2001).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344378\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:</i> Fixed doses (dosing which is independent of body weight or BSA), are used in some protocols (eg, testicular cancer); due to toxicity concerns, the same fixed dose should also be considered for obese patients (Griggs 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14717181\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pulmonary toxicity: Discontinue until determined not to be drug-related.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pulmonary diffusion capacity for carbon monoxide (DL<sub>CO</sub>) &lt;30% to 35% of baseline: Discontinue treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pulmonary diffusing capacity for carbon monoxide corrected for hemoglobin content [DLCOc] decrease of more than 25% during therapy (compared with baseline): Consider discontinuing bleomycin to avoid further pulmonary toxicity (Lauritsen 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141823\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 units (1 ea); 30 units (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 15 units (1 ea); 30 units (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141808\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F47062016\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units (1,000 international units = 1 USP unit).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141827\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: IV doses should be administered slowly over 10 minutes (according to the manufacturer's labeling).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM or SubQ: May cause pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrapleural: 60 units in 50 to 100 mL NS; use of topical anesthetics or opioid analgesia is usually not necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monitor for hypersensitivity, particularly following the first 2 doses in patients with lymphoma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130900\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).   </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141826\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Head and neck cancers:</b> Treatment of squamous cell carcinomas of the head and neck</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hodgkin lymphoma:</b> Treatment of Hodgkin lymphoma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Malignant pleural effusion:</b> Sclerosing agent for malignant pleural effusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <b>Testicular cancer:</b> Treatment of testicular cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25721944\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Germ cell tumors, malignant; Hodgkin lymphoma (pediatrics)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141898\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Bleomycin may be confused with Cleocin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Some products available internationally may have vial strength and dosing expressed as international units or milligrams (instead of units or USP units). Refer to prescribing information for specific strength and dosing information.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units (1,000 international units = 1 USP unit).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141815\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not always defined. The pathogenesis of respiratory adverse effects is not certain, but may be due to damage of pulmonary, vascular, or connective tissue. Response to steroid therapy is variable and somewhat controversial.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Phlebitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Tumor pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperpigmentation (50%), atrophic striae (&le;50%), erythema (&le;50%), exfoliation of the skin (&le;50%; particularly on the palmar and plantar surfaces of the hands and feet), hyperkeratosis (&le;50%), localized vesiculation (&le;50%), skin rash (&le;50%), skin sclerosis (&le;50%), alopecia (may be dose-related and reversible with discontinuation), nailbed changes (may be dose-related and reversible with discontinuation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Stomatitis (&le;30%), mucositis (&le;30%), anorexia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Febrile reaction (25% to 50%; acute)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Onycholysis, pruritus, thickening of skin</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylactoid reaction (including chills, confusion, fever, hypotension, wheezing; onset may be immediate or delayed for several hours; includes idiosyncratic reaction in 1% of lymphoma patients)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Scleroderma (diffuse)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Tachypnea (&le;5% to 10%), rales (&le;5% to 10%), interstitial pneumonitis (acute or chronic: &le;5% to 10%), pulmonary fibrosis (&le;5% to 10%), hypoxia (1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Angioedema, bone marrow depression (rare), cerebrovascular accident, cerebral arteritis, chest pain, coronary artery disease, hepatotoxicity, hyperpigmentation (flagellate), ischemic heart disease, malaise, myocardial infarction, nausea, nephrotoxicity, pericarditis, Raynaud&rsquo;s phenomenon, scleroderma (scleroderma-like skin changes), Stevens-Johnson syndrome, thrombotic thrombocytopenic purpura, toxic epidermal necrolysis, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141830\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to bleomycin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141812\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: May cause hepatic toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Idiosyncratic reaction:<b> [US Boxed Warning]: A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing (similar to anaphylaxis) has been reported in 1% of lymphoma patients treated with bleomycin.</b> Since these reactions usually occur after the first or second dose, careful monitoring is essential after these doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: <b>[US Boxed Warning]: Occurrence of pulmonary fibrosis (commonly presenting as pneumonitis; occasionally progressing to pulmonary fibrosis) is the most severe toxicity. Risk is higher in elderly patients or patients receiving &gt;400 units total lifetime dose;</b>  other possible risk factors include smoking and patients with prior radiation therapy or receiving concurrent oxygen (especially high inspired oxygen doses). A review of patients receiving bleomycin for the treatment of germ cell tumors suggests risk for pulmonary toxicity is increased in patients &gt;40 years of age, with glomerular filtration rate &lt;80 mL/minute, advanced disease, and cumulative doses &gt;300 units (O&rsquo;Sullivan 2003). Pulmonary toxicity may include bronchiolitis obliterans and organizing pneumonia (BOOP), eosinophilic hypersensitivity, and interstitial pneumonitis, progressing to pulmonary fibrosis (Sleijfer 2001); pulmonary toxicity may be due to a lack of the enzyme which inactivates bleomycin (bleomycin hydrolase) in the lungs (Morgan 2011; Sleijfer 2001), If pulmonary changes occur, withhold treatment and investigate if drug-related. In a study of patients with testicular cancer receiving bleomycin as part of the BEP regimen, pulmonary function testing (including forced vital capacity [FVC], forced expiratory volume in 1 second [FEV<sub>1</sub>], and diffusing capacity of the lungs for carbon monoxide [DLCO]) was performed prior to treatment, before each chemotherapy cycle, and then repeated at 1 year, 3 years, and 5 years during follow up; if the carbon monoxide diffusing capacity corrected for hemoglobin content [DLCOc] decreased more than 25% during therapy (compared with baseline), bleomycin was discontinued to avoid further pulmonary toxicity (Lauritsen 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: May cause renal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hodgkin lymphoma: Positron emission tomography/computed tomography (PET/CT) may have a role in determining early response to therapy in patients with Hodgkin lymphoma; a negative interim PET/CT result after 2 cycles may indicate that bleomycin can be safely omitted from the ABVD treatment regimen (Johnson 2016). Longer follow-up is necessary to determine the effect of bleomycin omission on long-term morbidity and mortality in these patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment (CrCl &lt;50 mL/minute), may require dose adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: In children, a younger age at treatment, cumulative dose &ge;400 units/m<sup>2</sup> (combined with chest irradiation), and renal impairment are associated with a higher incidence of pulmonary toxicity (Huang, 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; International issues: Some products available internationally may have vial strength and dosing expressed as international units or milligrams (instead of units or USP units). During shortages within the US, temporary importation of international products may be allowed by the FDA. The imported bleomycin vial and product labeling may express strength and dosing as international units instead of USP units. One USP unit of bleomycin = 1 mg (by potency) = 1,000 international units (Stefanou 2001). Refer to prescribing information for specific dosing information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; O<sub>2</sub> during surgery:  Use caution when administering O<sub>2</sub> during surgery to patients who have received bleomycin; the risk of bleomycin-related pulmonary toxicity is increased.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298875\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141817\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9160&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Filgrastim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemcitabine: May enhance the adverse/toxic effect of Bleomycin. The risk of pulmonary toxicity may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. Bleomycin may diminish the therapeutic effect of Lenograstim. Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of bleomycin infusion. Additionally, monitor patients more closely for signs/symptoms of bleomycin pulmonary toxicity when used with lenograstim (G-CSF).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased. Bleomycin may diminish the therapeutic effect of Lipegfilgrastim. Management: Lipegfilgrastim should be administered at least 24 hours after the completion of bleomycin. Consider monitoring for enhanced pulmonary toxicity when bleomycin and lipegfilgrastim are given in combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Bleomycin may decrease the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sargramostim: May enhance the adverse/toxic effect of Bleomycin. Specifically, the risk for pulmonary toxicity may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141819\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3013953\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. According to the manufacturer, women of childbearing potential should avoid becoming pregnant during bleomycin treatment. The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester and there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (Peccatori 2013). When multiagent therapy is needed to treat Hodgkin lymphoma during pregnancy, bleomycin (as a component of the ABVD [doxorubicin, bleomycin, vinblastine, and dacarbazine] regimen) may be used, starting with the second trimester (Follows 2014; Peccatori 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3013955\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if bleomycin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141821\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pulmonary function tests, including total lung volume, forced vital capacity, diffusion capacity for carbon monoxide; vital capacity, total lung capacity and pulmonary capillary blood volume may be better indicators of changes induced by bleomycin (Sleifjer 2001); forced vital capacity [FVC], forced expiratory volume in 1 second [FEV<sub>1</sub>], and diffusing capacity of the lungs for carbon monoxide [DLCO]) were performed prior to treatment, before each chemotherapy cycle, and then repeated at 1 year, 3 years, and 5 years during follow up for testicular cancer patients receiving bleomycin (Lauritsen 2016); chest x-ray, renal function, liver function; monitor for signs/symptoms of hypersensitivity; temperature initially; check body weight at regular intervals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141811\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bleomycin inhibits synthesis of DNA; binds to DNA leading to single- and double-strand breaks; also inhibits (to a lesser degree) RNA and protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141829\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: IM, SubQ, and intrapleural administration: 100%, 70%, and 45%, respectively, of IV serum concentrations</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 17.5 L/m<sup>2</sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 1% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Enzymatic inactivation by bleomycin hydrolase, a cytosolic cysteine proteinase enzyme; bleomycin hydrolase is widely distributed in normal tissues (except for the skin and lungs)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: IV: 2 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: IM, SubQ, Intrapleural: 30 to 60 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~65% [IV], 40% [Intrapleural])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323022\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Bleomycin Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 unit (1): $59.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 unit (1): $110.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F141832\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bemocin (ZW);</li>\n      <li>Bileco (AR);</li>\n      <li>Blenamax (AU, RU, SG, TW);</li>\n      <li>Blenoxane (BR, EC, EG, ZA);</li>\n      <li>Bleo (HK);</li>\n      <li>Bleocin (AE, BG, CZ, EE, EG, GR, HK, HN, HU, ID, IN, JO, JP, KR, KW, LB, LK, LT, MY, PE, PL, PT, QA, SA, SG, TH, TR, TW, VN);</li>\n      <li>Bleocin-S (MY);</li>\n      <li>Bleocina (UY);</li>\n      <li>Bleocip (ET, LB, ZW);</li>\n      <li>Bleocris (PY);</li>\n      <li>Bleolem (CO, MX, TH);</li>\n      <li>Bleomax (MX);</li>\n      <li>Bleomedac (SK);</li>\n      <li>Bleomicina (ES, IT);</li>\n      <li>Bleomycin (AT, CH, DK, FI, GB, NO, SE);</li>\n      <li>Bleomycin PFI (IL);</li>\n      <li>Bleomycine (BE, FR, LU, NL);</li>\n      <li>Bleomycinum (DE);</li>\n      <li>Bleonko (UA);</li>\n      <li>Blexit (CL);</li>\n      <li>Bloicin-S (PH);</li>\n      <li>Kupbloicin (VN);</li>\n      <li>Lyoble (LK);</li>\n      <li>Naprobleo (ET);</li>\n      <li>Naproplat (ET)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 97.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Azambuja E, Fleck JF, Batista RG, et al, &ldquo;Bleomycin Lung Toxicity: Who are the Patients With Increased Risk?&rdquo; <i>Pulm Pharmacol Ther</i>, 2005, 18(5):363-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/15939315/pubmed\" target=\"_blank\" id=\"15939315\">15939315</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blenoxane (bleomycin) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; April, 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleomycin [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA, LLC; February 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleomycin [prescribing information]. North Wales, PA: Teva Pharmaceuticals; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleomycin [product monograph]. Richmond Hill, ON: Fresenius Kabi Canada Ltd.; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carver JR, Shapiro CL, Ng A, et al, &ldquo;American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects,&rdquo; <i>J Clin Oncol</i>, 2007, 25(25):3991-4008.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/17577017/pubmed\" target=\"_blank\" id=\"17577017\">17577017</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Culine S, Kramar A, Th&eacute;odore C, et al, &ldquo;Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP,&rdquo; <i>J Clin Oncol</i>, 2008, 26(3):421-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/18202419/pubmed\" target=\"_blank\" id=\"18202419\">18202419</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"15226336\"></a>Cushing B, Giller R, Cullen JW, et al, &ldquo;Randomized Comparison of Combination Chemotherapy With Etoposide, Bleomycin, and Either High-Dose or Standard-Dose Cisplatin in Children and Adolescents With High-Risk Malignant Germ Cell Tumors: A Pediatric Intergroup Study -- Pediatric Oncology Group 9049 and Children's Cancer Group 8882,&rdquo; <i>J Clin Oncol</i>, 2004, 22(13):2691-700.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/15226336/pubmed\" target=\"_blank\" id=\"15226336\">15226336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dann EJ, Bar-Shalom R, Tamir A, et al, &ldquo;Risk-Adapted BEACOPP Regimen Can Reduce the Cumulative Dose of Chemotherapy for Standard and High-Risk Hodgkin Lymphoma With No Impairment of Outcome,&rdquo; <i>Blood</i>, 2007, 109(3):905-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/17018856/pubmed\" target=\"_blank\" id=\"17018856\">17018856</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25542311\"></a>Dharmarajan KV, Friedman DL, Schwartz CL, et al. Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group. <i>Int J Radiat Oncol Biol Phys</i>. 2015;92(1):60-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/25542311/pubmed\" target=\"_blank\" id=\"25542311\">25542311</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Wit R, Skoneczna I, Daugaard G, et al. &quot;Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983,&quot; <i> J Clin Oncol</i>. 2012;30(8):792-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/22271474/pubmed\" target=\"_blank\" id=\"22271474\">22271474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diehl V, Franklin J, Pfreundschuh M, et al, &ldquo;Standard and Increased-Dose BEACOPP Chemotherapy Compared With COPP-ABVD for Advanced Hodgkin's Disease,&rdquo; <i>N Engl J Med</i>, 2003, 348(24):2386-95.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/12802024/pubmed\" target=\"_blank\" id=\"12802024\">12802024</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Engert A, Franklin J, Eich HT, et al, &ldquo;Two Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final Results of the GHSG HD7 Trial,&rdquo; <i>J Clin Oncol</i>, 2007, 25(23):3495-502.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/17606976/pubmed\" target=\"_blank\" id=\"17606976\">17606976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo; <i>J Clin Oncol</i>, 2005, 23(30):7685-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/16234530/pubmed\" target=\"_blank\" id=\"16234530\">16234530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Follows GA, Ardeshna KM, Barrington SF, et al. Guidelines for the first line management of classical Hodgkin lymphoma.<i> Br J Haematol</i>. 2014;166(1):34-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/24712411 /pubmed\" target=\"_blank\" id=\"24712411 \">24712411 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25311218\"></a>Friedman DL, Chen L, Wolden S, et al. Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk hodgkin lymphoma: a report from the Children's Oncology Group Study AHOD0031. <i>J Clin Oncol</i>. 2014;32(32):3651-3658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/25311218/pubmed\" target=\"_blank\" id=\"25311218\">25311218</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"23182987\"></a>Gordon LI, Hong F, Fisher RI, et al. Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). <i>J Clin Oncol</i>. 2013;31(6):684-691.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/23182987/pubmed\" target=\"_blank\" id=\"23182987\">23182987</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10694546\"></a>Horning SJ, Williams J, Bartlett NL, et al, &ldquo;Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492,&rdquo; <i>J Clin Oncol</i>, 2000, 18(5):972-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/10694546/pubmed\" target=\"_blank\" id=\"10694546\">10694546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11821442\"></a>Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown BW, Rosenberg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. <i>J Clin Oncol.</i> 2002;20(3):630-637.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/11821442/pubmed\" target=\"_blank\" id=\"11821442\">11821442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hoskin PJ, Lowry L, Horwich A, et al, &ldquo;Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244,&rdquo; <i>J Clin Oncol</i>, 2009, 27(32):5390-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19738111/pubmed\" target=\"_blank\" id=\"19738111\">19738111</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huang TT, Hudson MM, Stokes DC, et al, &ldquo;Pulmonary Outcomes in Survivors of Childhood Cancer: A Systematic Review,&rdquo; <i>Chest</i>, 2011, 140(4): 881-901.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/21415131/pubmed\" target=\"_blank\" id=\"21415131\">21415131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9508171\"></a>Hutchinson RJ, Fryer CJ, Davis PC, et al, &ldquo;MOPP or Radiation in Addition to ABVD in the Treatment of Pathologically Staged Advanced Hodgkin's Disease in Children: Results of the Children's Cancer Group Phase III Trial,&rdquo; <i>J Clin Oncol</i>, 1998, 16(3):897-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/9508171/pubmed\" target=\"_blank\" id=\"9508171\">9508171</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ibrahimi OA and Anderson RR, &ldquo;Images in Clinical Medicine. Bleomycin-Induced Flagellate Hyperpigmentation,&rdquo; <i>N Engl J Med</i>, 2010, 363(24):e36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/21142531/pubmed\" target=\"_blank\" id=\"21142531\">21142531</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. <i>N Engl J Med</i>. 2016;374(25):2419-2429.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/27332902/pubmed\" target=\"_blank\" id=\"27332902\">27332902</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Johnson PW, Radford JA, Cullen MH, et al, &ldquo;Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519),&rdquo; <i>J Clin Oncol</i>, 2005, 23(36):9208-18.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/16314615/pubmed\" target=\"_blank\" id=\"16314615\">16314615</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"21079154\"></a>Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. <i>Blood</i>. 2011;117(9):2596-2603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/21079154/pubmed\" target=\"_blank\" id=\"21079154\">21079154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King PD and Perry MC, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo; <i>Oncologist</i>, 2001, 6(2):162-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/11306728/pubmed\" target=\"_blank\" id=\"11306728\">11306728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kung FH, Schwartz CL, Ferree CR,et al, &ldquo;POG 8625: A Randomized Trial Comparing Chemotherapy With Chemoradiotherapy for Children and Adolescents With Stages I, IIA, IIIA1 Hodgkin Disease: A Report From the Children's Oncology Group,&rdquo; <i>J Pediatr Hematol Oncol</i>, 2006, 28(6):362-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/16794504/pubmed\" target=\"_blank\" id=\"16794504\">16794504</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lam MS, &ldquo;The Need for Routine Bleomycin Test Dosing in the 21st Century,&rdquo; <i>Ann Pharmacother</i>, 2005, 39(11):1897-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/16219896/pubmed\" target=\"_blank\" id=\"16219896\">16219896</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lauritsen J, Kier MG, Bandak M, et al. Pulmonary function in patients with germ cell cancer treated with bleomycin, etoposide, and cisplatin. <i>J Clin Oncol</i>. 2016;34(13):1492-1499.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/26903578/pubmed\" target=\"_blank\" id=\"26903578\">26903578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo; <i>Lancet Oncol</i>, 2011, 12(8):806-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nichols CR, Catalano PJ, Crawford ED, et al, &ldquo;Randomized Comparison of Cisplatin and Etoposide and Either Bleomycin or Ifosfamide in Treatment of Advanced Disseminated Germ Cell Tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study,&rdquo; <i>J Clin Oncol</i>, 1998, 16(4):1287-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/9552027/pubmed\" target=\"_blank\" id=\"9552027\">9552027</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    O'Sullivan JM, Huddart RA, Norman AR, et al, &ldquo;Predicting the Risk of Bleomycin Lung Toxicity in Patients With Germ-Cell Tumours,&rdquo; <i>Ann Oncol</i>, 2003, 14(1):91-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/12488299/pubmed\" target=\"_blank\" id=\"12488299\">12488299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(Suppl 6):vi160-170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/23813932 /pubmed\" target=\"_blank\" id=\"23813932 \">23813932 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry MC. Chemotherapeutic agents: bleomycin. <i>The Chemotherapy Source Boo</i>k. 5th ed. Philadelphia, PA: 2012.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/12488299/pubmed\" target=\"_blank\" id=\"12488299\">12488299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19584400\"></a>Schwartz CL, Constine LS, Villaluna D, et al. A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. <i>Blood</i>. 2009;114(10):2051-2059.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19584400/pubmed\" target=\"_blank\" id=\"19584400\">19584400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sleijfer S, &ldquo;Bleomycin-Induced Pneumonitis,&rdquo; <i>Chest</i>, 2001, 120(2):617-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/11502668/pubmed\" target=\"_blank\" id=\"11502668\">11502668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stefanou A, MacCallum P, and Siderov J. Errors due to bleomycin nomenclature. BMJ 2001;322(7299):548.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Straus DJ, Portlock CS, Qin J, et al, &ldquo;Results of a Prospective Randomized Clinical Trial of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) Followed by Radiation Therapy (RT) Versus ABVD Alone for stages I, II, and IIIA Nonbulky Hodgkin Disease,&rdquo; <i>Blood</i>, 2004, 104(12):3483-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/15315964/pubmed\" target=\"_blank\" id=\"15315964\">15315964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tobias JS, Monson K, Gupta N, et al, &ldquo;Chemoradiotherapy for Locally Advanced Head and Neck Cancer: 10-year Follow-Up of the UK Head and Neck (UKHAN1) Trial,&rdquo; <i>Lancet Oncol</i>, 2010, 11(1):66-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19875337/pubmed\" target=\"_blank\" id=\"19875337\">19875337</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wiernik PH, Hong F, Glick JH, et al, &ldquo;Radiation Therapy Compared With Chemotherapy for Consolidation of Chemotherapy-Induced Remission of Advanced Hodgkin Lymphoma: A Study by the Eastern Co-Operative Oncology Group (E1476) With &gt;20 Years Follow-Up,&rdquo; <i>Leuk Lymphoma</i>, 2009, 50(10):1632-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/19863338/pubmed\" target=\"_blank\" id=\"19863338\">19863338</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7512129\"></a>Williams S, Blessing JA, Liao SY, et al, &ldquo;Adjuvant Therapy of Ovarian Germ Cell Tumors With Cisplatin, Etoposide, and Bleomycin: A Trial of the Gynecologic Oncology Group,&rdquo; <i>J Clin Oncol</i>, 1994, 12(4):701-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bleomycin-drug-information/abstract-text/7512129/pubmed\" target=\"_blank\" id=\"7512129\">7512129</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9160 Version 158.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708640\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F141845\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F141887\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F141849\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F141871\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F14717786\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F141851\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F5526919\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20344378\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F14717181\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F141823\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F141808\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F47062016\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F141827\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130900\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F141826\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25721944\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F141898\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F141815\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F141830\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F141812\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298875\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F141817\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F141819\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3013953\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3013955\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F141821\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F141811\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F141829\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323022\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F141832\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9160|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bleomycin-patient-drug-information\" class=\"drug drug_patient\">Bleomycin: Patient drug information</a></li><li><a href=\"topic.htm?path=bleomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Bleomycin: Pediatric drug information</a></li></ul></div></div>","javascript":null}